Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHENOMANAL: Phenobarbital for Severe Alcohol Withdrawal
NCT03586089Terminated
- Sponsor
- Unity Health Toronto
- Start
- Jun 2021
- Primary completion
- Jul 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Randomised, double-blind trial in alcohol withdrawal syndrome (AWS) comparing Phenobarbital with Placebo (2 arms). Primary endpoint: Adverse Event Rate at 18 months. Started Jun 2021; status: terminated.
02
Drugs
phenobarbital
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT03586089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586089.